Search results for "Atopic"

showing 10 items of 100 documents

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells

2018

CD38 is overexpressed by multiple myeloma cells and has emerged as a target for therapeutic antibodies. Nanobodies are soluble single domain antibody fragments derived from the VHH variable domain of heavy chain antibodies naturally occurring in camelids. We previously identified distinct llama nanobodies that recognize three non-overlapping epitopes of the extracellular domain of CD38. Here, we fused these VHH domains to the hinge, CH2, and CH3 domains of human IgG1, yielding highly soluble chimeric llama/human heavy chain antibodies (hcAbs). We analyzed the capacity of these hcAbs to mediate complement-dependent cytotoxicity (CDC) to CD38-expressing human multiple myeloma and Burkitt lymp…

0301 basic medicinelcsh:Immunologic diseases. AllergyRecombinant Fusion ProteinsImmunologyAntineoplastic AgentsEpitope03 medical and health sciencesbiparatopic antibodiesAntigens Neoplasmhemic and lymphatic diseasesCell Line TumorAntibodies BispecificImmunology and AllergyAnimalsHumansCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchHeavy-chain antibodybiologyheavy chain antibodyantibody engineeringChemistryAntibody-Dependent Cell CytotoxicityDaratumumabAntibodies MonoclonalComplement System ProteinsSingle-Domain AntibodiesADP-ribosyl Cyclase 1Complement-dependent cytotoxicityCell biologymultiple myelomananobody030104 developmental biologySingle-domain antibodyCell culturebiology.proteinEpitopes B-LymphocyteImmunotherapyAntibodylcsh:RC581-607Immunoglobulin Heavy ChainsCamelids New WorldCD38Frontiers in Immunology
researchProduct

Predictability of early atopy by cord blood-IgE and parental history.

1997

Summary Background Atopic family history and cord blood IgE have been used as predictors of atopic disease in newborns for about 20 years, but at least for cord blood IgE the sensitivity has been shown to be very low. The objective of this paper was to evaluate whether parental history and cord blood-IgE were more accurate predictors for the appropriate atopic phenotypes in the infants rather than for any atopy. Methods A total of 1314 newborn infants was recruited in six German obstetric departments in 1990 and followed-up for 2 years. Four hundred and ninty-ninc (38%) were at high risk for atopy with at least two first degree atopic family members and/or elevated cord-blood IgE concentrat…

AdultHypersensitivity ImmediateAllergyPediatricsmedicine.medical_specialtyImmunologyImmunoglobulin EAtopyCohort StudiesPregnancyRisk FactorsGermanyImmunology and AllergyMedicineHumansCumulative incidenceProspective StudiesFamily historyAsthmaFamily Healthbiologybusiness.industryInfant NewbornInfantAtopic dermatitisImmunoglobulin Emedicine.diseaseFetal BloodPhenotypeCord bloodbiology.proteinFemalebusinessClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Interaction between filaggrin mutations and neonatal cat exposure in atopic dermatitis

2020

Atopic dermatitis (AD) is a prevalent inflammatory skin disease. Loss-of-function mutations in filaggrin gene (FLG) represent the strongest genetic risk factors for AD, being strongly associated with early disease onset and persistence into adulthood.1 The epidermis of individuals with mutations in FLG is fundamentally different from normal skin being characterized by increased penetration of allergens.2 Recent birth cohort studies showed a significant interaction between cat ownership at birth and mutations in FLG (R501X, 2282del4) on the development of early-onset AD.3 This finding was replicated for the 2282del4 FLG mutation in a Dutch cohort study, and extended to further associate with…

AllergyAllergyImmunologyFilaggrin ProteinsDermatitis Atopic03 medical and health sciences0302 clinical medicineCAT EXPOSUREIntermediate Filament ProteinsmedicineImmunology and AllergyAnimalsHumansGenetic Predisposition to Disease030304 developmental biologyRISK0303 health sciencesScience & TechnologyCATSbusiness.industryInfant NewbornAtopic dermatitismedicine.disease030228 respiratory system1107 ImmunologyMutation (genetic algorithm)ImmunologyMutationCatsbusinessLife Sciences & BiomedicineFilaggrinAllergy
researchProduct

Immunoadsorption for treatment of severe atopic dermatitis.

2017

Atopic dermatitis (AD) is a common disease affecting up to 10-20% of the population with the largest disease burden in childhood. Treatment options include basic emollient treatment, topical as well as systemic immunosuppressants. The pathogenesis is complex and among various triggers, genetic predisposition and immunological alterations contribute to development of disease. Atopy is common in patients with AD and many patients have high levels of Immunoglobulin E (IgE), some of which recognizes exogenous or auto/self-allergens. Treatment options targeting IgE such as specific immunotherapy against e.g. house dust mites or using anti-IgE antibodies (omalizumab) showed variable results that …

0301 basic medicinemedicine.medical_specialtyPopulationOmalizumabDiseaseImmunoglobulin ESeverity of Illness IndexDermatitis AtopicAtopy030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal MedicinemedicineGenetic predispositionHumanseducationImmunoadsorptionImmunosorbent Techniqueseducation.field_of_studybiologybusiness.industryGeneral MedicineAtopic dermatitisImmunoglobulin Emedicine.diseaseDermatologyUp-Regulation030104 developmental biologyTreatment OutcomeImmunologybiology.proteinCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugAtherosclerosis. Supplements
researchProduct

Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%

2020

Background Exfoliative and erosive cheilitis, may be a source of speech and chewing discomfort, but may also be an aesthetic issue for the patients affected. Such a clinical presentation may implicate a variety of inflammatory conditions, including atopic (eczematous) cheilitis. Topical and systemic agents, e.g. corticosteroids, have been used to treat inflammatory lip conditions. Topical tacrolimus has also been used in some inflammatory lip conditions. Material and Methods We performed a retrospective clinical analysis of atopic cheilitis patients. Results Between 2015 and 2020, we addressed 7 (seven) patients with atopic dermatitis affecting only lips and were diagnosed as atopic-eczemat…

osseodensificationprimary stabilitymedicine.medical_specialtyAdministration TopicalEsthetics DentalTacrolimuslow density boneAtopymedicineHumansGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesrfaOral Medicine and PathologyClinical pathologybusiness.industryResearchAtopic dermatitisTopical tacrolimusmedicine.diseaseDermatologyLipTacrolimusbody regionsstomatognathic diseasesTreatment OutcomeCheilitisOtorhinolaryngologyConcomitantSurgerybusinessImmunosuppressive AgentsMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Therapeutic application of T cell receptor mimic peptides or cDNA in the treatment of T cell-mediated skin diseases

2000

An 8-amino acid peptide encoding a sequence of the transmembrane region of the T cell receptor alpha chain (TCR-alpha) was shown to inhibit T cell function by preventing functional assembly of the T cell receptor (mimic peptide). To avoid systemic immunosuppression by peptide application in vivo, we used a topical application of the peptide. In the system of murine contact sensitivity, topical application of the peptide inhibited the elicitation of contact sensitivity following application of a contact allergen in sensitized animals. Alternatively, when naked DNA encoding the peptide sequence was injected into skin before application of a contact allergen to sensitized animals, local immuno…

DNA ComplementaryReceptors Antigen T-Cell alpha-betaT-LymphocytesT cellGenetic enhancementPeptidePharmacologyBiologySkin DiseasesDermatitis AtopicMiceAntigenVaccines DNAGeneticsmedicineAnimalsHumansReceptorMolecular BiologyPeptide sequenceImmunosuppression Therapychemistry.chemical_classificationMice Inbred BALB CT-cell receptorAllergensPeptide Fragmentsmedicine.anatomical_structurechemistryNaked DNADermatitis Allergic ContactImmunologyMolecular MedicineGene Therapy
researchProduct

A Highly Decreased Binding of Cyclic Adenosine Monophosphate to Protein Kinase A in Erythrocyte Membranes is Specific for Active Psoriasis

2002

A cyclic adenosine monophosphate binding abnormality in psoriatic erythrocytes that could be corrected by retinoid treatment has been reported. It was tested whether this binding abnormality is specific for psoriasis and the effects of treatment were compared with etretinate, cyclosporine A, or anthralin on 2-(3)H-8-N(3)-cyclic adenosine monophosphate binding to the regulatory subunit of protein kinase A in erythrocyte membranes. One hundred and fifteen individuals were evaluated, including: (i) 34 healthy persons; (ii) 15 patients with nonatopic inflammatory skin diseases (eczema, erythroderma, tinea, Grover's disease, erysipelas, urticaria); (iii) eight with other dermatoses mediated by i…

AdultMaleAzidesmedicine.medical_specialtyAdolescentmedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsErythrodermaEtretinateDermatologySeverity of Illness IndexBiochemistryRetinoidschemistry.chemical_compoundPsoriasis Area and Severity IndexKeratolytic AgentsPsoriasis Area and Severity IndexPsoriasisInternal medicineCyclic AMPmedicineHumansPsoriasisCyclic adenosine monophosphateRetinoidMolecular BiologydermatitisAgedErythema nodosumbusiness.industryErythrocyte MembraneAffinity LabelsCell BiologyAtopic dermatitisAnthralinMiddle Agedmedicine.diseaseCyclic AMP-Dependent Protein KinasesEndocrinologychemistryEtretinateCyclosporineFemaleDermatologic Agentsbusinesscyclosporine AProtein Bindingmedicine.drugJournal of Investigative Dermatology
researchProduct

Foetal exposure to heavy metals and risk of atopic diseases in early childhood

2020

International audience; Background: Accumulating evidence suggests that in utero exposures can influence the development of the immune system and thus contribute to disease development. Studies investigating the association between prenatal exposures to heavy metals and atopic diseases, however, are scarce.Methods: Children from the EDEN birth cohort were prospectively followed up using parental questionnaires with validated questions on asthma, allergic rhinitis, eczema, and food allergy symptoms. The questionnaires were administered every 4 months during the children's first year, and then every year until the age of 5, with a final survey at the age of 8. Serum concentrations of lead (Pb…

Maleatopic dermatitiAllergycadmium[SDV]Life Sciences [q-bio]ImmunologyPhysiology010501 environmental sciences01 natural sciencesDermatitis Atopic03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaFood allergyPregnancyMetals HeavymedicineImmunology and AllergyHumans0105 earth and related environmental sciencesAsthmafood allergyleadatopic dermatitisbusiness.industryIncidence (epidemiology)Hazard ratioInfantAtopic dermatitisasthmamedicine.diseaseallergyRhinitis Allergic3. Good healthin utero exposure[SDV] Life Sciences [q-bio]030228 respiratory systemIn uteroCord bloodChild PreschoolPediatrics Perinatology and Child HealthmanganeseFemaleeczemabusinessFood Hypersensitivity
researchProduct

Air Pollution and Recent Symptoms of Asthma, Allergic Rhinitis, and Atopic Eczema in Schoolchildren Aged Between 6 and 7 Years

2008

Abstract Objective The objective of the study was to analyze the relationship between air pollutants and the prevalence of recent symptoms of asthma, allergic rhinitis, and atopic eczema in schoolchildren aged between 6 and 7 years. Patients and Methods The prevalence of recent (previous 12 months) symptoms of allergic diseases was obtained by means of the questionnaire of the International Study of Asthma and Allergies in Childhood (ISAAC), Spain, with the participation of 7 centers (Asturias, Barcelona, Bilbao, Cartagena, La Coruna, Madrid, and Valencia) and 20 455 schoolchildren aged between 6 and 7 years, from 2002 to 2003. The pollutant detection systems of the aforementioned centers p…

MalePediatricsmedicine.medical_specialtyAllergyRhinitis Allergic PerennialMeteorological ConceptsUrban PopulationSevere asthmaNitrogen DioxideAnnual averageAir pollutionmedicine.disease_causeDermatitis AtopicAir PollutionEnvironmental healthPrevalenceHumansSulfur DioxideMedicineChildRespiratory SoundsAsthmaAir PollutantsCarbon Monoxidebusiness.industryDry coughRhinitis Allergic SeasonalGeneral MedicineOdds ratiomedicine.diseaseAsthmaConfidence intervalCoughSpainFemaleParticulate MatterbusinessArchivos de Bronconeumología ((English Edition))
researchProduct

Current therapeutical strategies for allergic rhinitis

2018

Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option.This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the…

Allergen immunotherapyRhinitis allergicTreatment outcomeHistamine Antagonistsmacromolecular substancesmedicine.disease_cause03 medical and health sciences0302 clinical medicineAllergenimmune system diseasesmedicineHumansPharmacology (medical)AsthmaPharmacologybusiness.industryHistamine antagonistsGeneral MedicineAtopic dermatitisrespiratory systemmedicine.diseaseRhinitis Allergicrespiratory tract diseasesbody regionsTreatment OutcomeDesensitization Immunologic030220 oncology & carcinogenesisImmunologybusiness030217 neurology & neurosurgeryExpert Opinion on Pharmacotherapy
researchProduct